Iovance Biotherapeutics Names Noah Berkowitz CMO
(RTTNews) - Iovance Biotherapeutics (IOVA), a biotechnology company, on Thursday announced the appointment of Noah Berkowitz as Chief Medical Officer, effective September 30.
Berkowitz joins the company from Arvinas Pharmaceuticals (ARVN) as Chief Medical Officer.
The company said Berkowitz will lead its global drug development efforts as it advances its tumor-infiltrating lymphocyte therapy platform across multiple solid tumor cancers.
The company appointed Berkowitz as CMO following the retirement of former CMO Friedrich Graf Finckenstein in June 2026.
In the pre-market trading, Iovance Biotherapeutics is 0.26% higher at $14.86 on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.